The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The German group hopes to expand its colorectal cancer offering, taking on the only SLC6A8 inhibitor in development.
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T.
Five years after Affimed switched to NK cell engagers investors will see the fruits of a potentially registrational trial.
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
As the biotech markets turned bullish the sector’s ups and downs continued.